Home  |  Contact
Due to maintenance work, this service will be unavailable Mon Feb 13 between 07:00 and 09:30 - CET. Apologies for the inconvenience.

Cellosaurus WRO (CVCL_0582)

[Text version]

Cell line name WRO
Synonyms WRO82-1; WRO 82-1; WRO-82; WRO82; UCLA RO 82-W-1; UCLA RO-82W-1; UCLA RO82W1; RO82W1; RO 82 W-1; RO82-W-1; RO82W-1; RO82
Accession CVCL_0582
Secondary accession CVCL_1663
Resource Identification Initiative To cite this cell line use: WRO (RRID:CVCL_0582)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Doubling time: 4 days (PubMed=2570483).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Mitochondrial genome sequenced.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North1.32
East Asian, South3.34
South Asian7.27
European, North24
European, South61.74
Disease Thyroid gland follicular carcinoma (NCIt: C8054)
Differentiated thyroid carcinoma (ORDO: Orphanet_146)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DepMap; ICLC

D16S53911,12 (DepMap; ICLC)
12 (Cosmic-CLP)
Penta D10
Penta E19,20
vWA16,19 (Cosmic-CLP; DepMap)
16,21 (ICLC)

Run an STR similarity search on this cell line

PubMed=2551628; DOI=10.1210/endo-125-4-1783
Pang X.-P., Hershman J.M., Chung M., Pekary A.E.
Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin.
Endocrinology 125:1783-1788(1989)

PubMed=2570483; DOI=10.1007/BF02899078
Estour B., Van Herle A.J., Juillard G.J.-F., Totanes T.L., Sparkes R.S., Giuliano A.E., Klandorf H.
Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1).
Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 57:167-174(1989)

PubMed=8423216; DOI=10.1172/JCI116168
Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P.
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
J. Clin. Invest. 91:179-184(1993)

PubMed=9348181; DOI=10.1210/endo.138.11.5509
Nishihara E., Nagayama Y., Mawatari F., Tanaka K., Namba H., Niwa M., Yamashita S.
Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo.
Endocrinology 138:4577-4583(1997)

PubMed=11439348; DOI=10.1038/sj.onc.1204531
Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.J.
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.
Oncogene 20:3845-3856(2001)

Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

PubMed=16778181; DOI=10.1158/0008-5472.CAN-06-0171
Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A., Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G., Rugolo M., Romeo G.
Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.
Cancer Res. 66:6087-6096(2006)

PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026
van Staveren W.C.G., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113-8120(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133.1-133.9(2012)

PubMed=25675381; DOI=10.1210/jc.2014-2764
von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J., Tun H.W., Smallridge R.C., Copland J.A.
Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
J. Clin. Endocrinol. Metab. 100:E697-E709(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections ECACC; 92030502
ICLC; HTL98002
Cell line databases/resources CLO; CLO_0008860
MCCL; MCC:0000488
CLDB; cl4167
CLDB; cl4902
Cell_Model_Passport; SIDM00218
Cosmic-CLP; 930083
DepMap; ACH-001384
Lonza; 1209
TOKU-E; 4066
Anatomy/cell type resources BTO; BTO:0004772
Chemistry resources ChEMBL-Cells; CHEMBL3308779
ChEMBL-Targets; CHEMBL1075565
GDSC; 930083
PharmacoDB; RO82W1_1322_2019
PubChem_Cell_line; CVCL_0582
Encyclopedic resources Wikidata; Q54994417
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM827437
GEO; GSM1670384
Polymorphism and mutation databases Cosmic; 684194
Cosmic; 685606
Cosmic; 849971
Cosmic; 886554
Cosmic; 918181
Cosmic; 928830
Cosmic; 930083
Cosmic; 931244
Cosmic; 990535
Cosmic; 1005459
Cosmic; 1094762
Cosmic; 1152113
Cosmic; 1155332
Cosmic; 1161614
Cosmic; 1162842
Cosmic; 1280051
Cosmic; 1699415
Cosmic; 2319849
IARC_TP53; 2130
IARC_TP53; 27230
Progenetix; CVCL_0582
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update15-Dec-2022
Version number35